TCG Lifesciences Pvt. Ltd., a company controlled by New York-based The Chatterjee Group, has expanded its operations in the U.S. with the establishment of TCG GreenChem Inc., a subsidiary of TCG Lifesciences to provide contract development and manufacturing organization (CDMO) services to global clients. TCG GreenChem offers CMC development services including process research and development and delivery of cGMP APIs. It aims at utilizing its deep expertise in areas of automated catalysis/reaction screening, reaction optimization, and continuous chemistry to support the needs of the big pharma and biotech industry. It has a robust pipeline of projects with its customers to manage their entire portfolios, offering integrated CMC and supply of APIs from early clinical trials to commercialization.
 
TCG GreenChem is developing novel, efficient and low-cost processes for selected COVID-19 virus related medicines and other antiviral drugs using new technologies and process schemes under contract with research foundations/hospitals, U.S. Government, and selected biotech companies. It is also engaged with developing several selected drugs with backward integration all the way to the starting materials within U.S. shores. TCG GreenChem operates out of a 3,000 SFT lab space in Richmond, Virginia’s VCU’s Biotechnology Research Park with access to state-of-the-art facilities. It also occupies 54,000 SFT lab/office spacein New Jersey in the Princeton South Corporate Center, a one-of-a-kind process research and development facility including cGMP capabilities.
 
“The priority of our customers today is to find ways to leverage their external partners to fill up a large part of their product development needs,” said Swapan Bhattacharya, managing director, TCG Lifesciences Pvt. Ltd. “In order to become their preferred partners, we need to provide high quality, efficient and low-cost services which are only possible if we deploy high-end talents and skills that can drive innovation. TCG GreenChem has an exceptional management team, technological expertise and know-how, which is critical for the development of architecturally complex intermediates and APIs by utilizing state-of-the-art synthetic organic chemistry.”
 
Chris Senanayake, CEO and CSO, TCG GreenChem, said, “We are excited to be a part of TCG Lifesciences Pvt. Ltd., as they are highly valued by their pharmaceutical partners and have a reputation of embracing innovation and high-end technology which are the cornerstones of the TCG GreenChem’s strategy. Our mission is to create a ‘technology innovator’ CDMO, to partner with the pharmaceutical, biotechnology, and generic industries in delivering integrated, accelerated, and economical services utilizing green sustainable technologies with a global footprint. Leveraging our knowledge of drug development and commercialization, we want to be the Drug Development Engine ‘Accelerating Molecules to Medicines’ by advancing preclinical candidates into phase I and beyond, for our clients and partners.”